JD Supra1d
GTCR / Surmodics: Four Key Takeaways for M&A Antitrust from the First FTC Merger Challenge Under Trump
In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...
GlobalData on MSN3d
FTC sues to block GTCR’s ‘unlawful acquisition’ of Surmodics
GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...
JD Supra10h
FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals
On March 6, 2025, the Federal Trade Commission (FTC) filed a lawsuit in federal court challenging GTCR BC Holdings, LLC's (GTCR) proposed ...
Crain's Chicago Business6d
FTC targets GTCR in agency's first merger challenge under new Trump term
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Fierce Biotech6d
FTC sues to block Surmodics acquisition by private equity over device coating competition
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...
Why Surmodics Stock Is Falling On Friday
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
Zacks Investment Research on MSN6d
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
Surmodics, Inc. SRDX recently provided a statement in response to the U.S. Federal Trade Commission (“FTC”) blocking the ...
FTC Sues GTCR, Surmodics Over Medical Device Coatings Deal (1)
The Federal Trade Commission sued Thursday to block private equity firm GTCR BC Holdings’ acquisition of Surmodics Inc., ...
Surmodics upgraded to Buy from Hold at Lake Street
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
Modern Healthcare7d
FTC sues to block GTCR’s $627M Surmodics acquisition
The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.